Key facts
- It has raised $14.2M; the latest was Early Stage VC ($14.2M) in Dec 2025.
- Notable investors include Nanjing Innovation Capital Group, Dingxin Capital, Fosun Health Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Otovia
- ·The full record, as it builds
Funding rounds
No funding rounds for Otovia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Otovia
Manufacturer of advanced biotechnology products intended to accelerate drug discovery and therapeutic innovation. The company offers proprietary small molecule platforms, translational research expertise, and patent-backed drug pipelines, enabling pharmaceutical enterprises and research institutions to create effective treatments for complex diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Website
- otoviatx.com/
- Ownership
- Privately Held (backing)
Otovia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Otovia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Otovia in its N-PORT filings yet. We sweep new filings monthly.